Citigroup Inc Pro Qr Therapeutics N.V. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.8 - $3.7 $728 - $3,370	-911 Reduced 92.3%	76 $0
Q3 2022 Nov 10, 2022	SELL	$0.74 - $0.89 $204 - $245	-276 Reduced 21.85%	987 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.56 - $1.0 $5,628 - $10,051	-10,051 Reduced 88.84%	1,263 $1,000
Q1 2022 May 12, 2022	SELL	$0.9 - $8.39 $4,126 - $38,468	-4,585 Reduced 28.84%	11,314 $10,000
Q4 2021 Feb 10, 2022	SELL	$6.58 - $8.44 $88,073 - $112,969	-13,385 Reduced 45.71%	15,899 $127,000
Q3 2021 Nov 10, 2021	BUY	$5.16 - $8.47 $151,105 - $248,035	29,284 New	29,284 $245,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $188M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.